Abstract
Objective: This study aims to evaluate the clinical efficacy of Cyberknife for treating colorectal cancer (CRCa) patients with liver metastases. Methods: Data of 22 CRCa patients with liver metastases were retrospectively studied. All patients were admitted to Tianjin Cancer Hospital from October 2006 to May 2012. They were implanted with a gold marker in the lesions or around the tumor less than 2 cm under computer tomography or ultrasound. The total radiation dose was (39-50) Gy/(3-6) fractions according to the location of liver metastases. None received concurrent chemotherapy during Cyberknife radiotherapy. Results:All patients successfully completed the Cyberknife treatment. The median overall survival was 50 months (range, 15 to 55 months). The one-, two-, and three-year survival rates were 100%, 94%, and 72.5%, respectively. The median progression-free survival was 28 months (range, 2.3 to 44 months). The local control for one year or more was 82.6%. The patients that received systemic therapy before Cyberknife showed relatively good local control (P= 0.07). The most common toxicity was grade 1 or 2 nausea, vomiting, and weakness. No grade Ⅲ or worse acute toxicity was found. No late toxicity was also observed. Conclusion: Cyberknife is a safe and effective treatment for CRCa patients with liver metastases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
